Literature DB >> 19377967

Imaging specific cell surface protease activity in living cells using reengineered bacterial cytotoxins.

John P Hobson1, Shihui Liu, Stephen H Leppla, Thomas H Bugge.   

Abstract

The scarcity of methods to visualize the activity of individual cell surface proteases in situ has hampered basic research and drug development efforts. In this chapter, we describe a simple, sensitive, and noninvasive assay that uses nontoxic reengineered bacterial cytotoxins with altered protease cleavage specificity to visualize specific cell surface proteolytic activity in single living cells. The assay takes advantage of the absolute requirement for site-specific endoproteolytic cleavage of cell surface-bound anthrax toxin protective antigen for its capacity to translocate an anthrax toxin lethal factor-beta-lactamase fusion protein to the cytoplasm. A fluorogenic beta-lactamase substrate is then used to visualize the cytoplasmically translocated anthrax toxin lethal factor-beta-lactamase fusion protein. By using anthrax toxin protective antigen variants that are reengineered to be cleaved by furin, urokinase plasminogen activator, or metalloproteinases, the cell surface activities of each of these proteases can be specifically and quantitatively determined with single cell resolution. The imaging assay is excellently suited for fluorescence microscope, fluorescence plate reader, and flow cytometry formats, and it can be used for a variety of purposes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19377967      PMCID: PMC2753202          DOI: 10.1007/978-1-60327-003-8_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  26 in total

1.  Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.

Authors:  S Liu; T H Bugge; S H Leppla
Journal:  J Biol Chem       Date:  2001-03-12       Impact factor: 5.157

2.  Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter.

Authors:  G Zlokarnik; P A Negulescu; T E Knapp; L Mere; N Burres; L Feng; M Whitney; K Roemer; R Y Tsien
Journal:  Science       Date:  1998-01-02       Impact factor: 47.728

3.  Rapid and efficient site-directed mutagenesis by single-tube 'megaprimer' PCR method.

Authors:  S H Ke; E L Madison
Journal:  Nucleic Acids Res       Date:  1997-08-15       Impact factor: 16.971

Review 4.  Cysteine cathepsins: multifunctional enzymes in cancer.

Authors:  Mona Mostafa Mohamed; Bonnie F Sloane
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

Review 5.  Anthrax toxins.

Authors:  N S Duesbery; G F Vande Woude
Journal:  Cell Mol Life Sci       Date:  1999-09       Impact factor: 9.261

Review 6.  The plasminogen activation system in tumor growth, invasion, and metastasis.

Authors:  P A Andreasen; R Egelund; H H Petersen
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

7.  Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin.

Authors:  S Liu; S Netzel-Arnett; H Birkedal-Hansen; S H Leppla
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

Review 8.  Anthrax toxin: structures, functions and tumour targeting.

Authors:  Shihui Liu; Rebecca L Schubert; Thomas H Bugge; Stephen H Leppla
Journal:  Expert Opin Biol Ther       Date:  2003-08       Impact factor: 4.388

9.  Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases.

Authors:  V M Gordon; K R Klimpel; N Arora; M A Henderson; S H Leppla
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.609

10.  Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides.

Authors:  N Arora; S H Leppla
Journal:  J Biol Chem       Date:  1993-02-15       Impact factor: 5.486

View more
  6 in total

1.  High-throughput protease activity cytometry reveals dose-dependent heterogeneity in PMA-mediated ADAM17 activation.

Authors:  Lidan Wu; Allison M Claas; Aniruddh Sarkar; Douglas A Lauffenburger; Jongyoon Han
Journal:  Integr Biol (Camb)       Date:  2015-04-02       Impact factor: 2.192

2.  Mechanism of FGF23 processing in fibrous dysplasia.

Authors:  Nisan Bhattacharyya; Malgorzata Wiench; Claudia Dumitrescu; Brian M Connolly; Thomas H Bugge; Himatkumar V Patel; Rachel I Gafni; Natasha Cherman; Monique Cho; Gordon L Hager; Michael T Collins
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

3.  Electroosmotic sampling. Application to determination of ectopeptidase activity in organotypic hippocampal slice cultures.

Authors:  Hongjuan Xu; Yifat Guy; Amy Hamsher; Guoyue Shi; Mats Sandberg; Stephen G Weber
Journal:  Anal Chem       Date:  2010-08-01       Impact factor: 6.986

4.  Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases.

Authors:  Nadire Duru; Nisha R Pawar; Erik W Martin; Marguerite S Buzza; Gregory D Conway; Rena G Lapidus; Shihui Liu; Jocelyn Reader; Gautam G Rao; Dana M Roque; Stephen H Leppla; Toni M Antalis
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-08       Impact factor: 12.779

5.  Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.

Authors:  Erik W Martin; Marguerite S Buzza; Kathryn H Driesbaugh; Shihui Liu; Yolanda M Fortenberry; Stephen H Leppla; Toni M Antalis
Journal:  Oncotarget       Date:  2015-10-20

Review 6.  Tumor Targeting and Drug Delivery by Anthrax Toxin.

Authors:  Christopher Bachran; Stephen H Leppla
Journal:  Toxins (Basel)       Date:  2016-07-01       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.